Few cases in recent years have generated as much excitement in India and across the world as Novartis’ bid for patenting its cancer drug Glivec in India. India’s Supreme Court delivered its verdict on April 1, 2013, on the case bringing to closure a 7 year-old legal battle. Novartis lost. But challenges and questions remain.
Here are web links to my reports/podcasts on the subject
1. http://www.lancet.com/journals/lancet/article/PIIS0140-6736(13)60826-0/fulltext (The Lancet, The World Report)
2. http://download.thelancet.com/flatcontentassets/audio/lancet-news/2013/12april.mp3 (The Lancet, podcast)
3. http://www.dnaindia.com/analysis/1820025/column-india-pariah-or-pathbreaker-of-pharma-world (Column, Edgy Nation, DNA)
4. http://www.ip-watch.org/2013/04/01/novartis-loses-patent-bid-lessons-from-indias-3d-experience/ (Report, Intellectual Property Watch)